Abstract Details

Title ANCHOR-CD (AbobotulinumtoxinA Neurotoxin: Clinical and Health Economics Outcomes Registry in Cervical Dystonia): A Multicenter, Observational Study of Dysport in Cervical Dystonia: Baseline Data and Cycle One Efficacy Data

Topic Movement Disorders

Presentation(s) P07 - (-)

Poster/Presentation
Number 191

Objective

Background BACKGROUND: ANCHOR-CD is an open-label, observational study in the U.S. with target enrollment of 400 idiopathic CD patients treated with abobotulinumtoxinA.

Design/Methods DESIGN/METHODS: Assessments include: The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), Pain Numeric Rating Scale (NRS), Clinical Global Impression of Change (CGIC), Patient Global Impression of Change (PGIC), and Treatment Satisfaction Questionnaire for Medication (TSQM).

Results RESULTS: Initial treatment data from an ongoing study of cervical dystonia patients was collected on July 26, 2012 from 209 patients enrolled at 33 US clinical sites. The types of dystonic neck posturing included torticollis (85.4%), laterocollis (54.9%), retrocollis (24.3%), and anterocollis (15.5%). Of the 209 patients, 156 (75%) were previously treated with botulinum toxin therapy: 102/156 (66%) were switched from onabotulinumtoxinA (Botox), and 32/156 (21%) subjects continued on abobotulinumtoxinA. The median cycle one abobotulinumtoxinA dose was 500 Units. The most frequently injected muscles were the splenius capitis, trapezius, levator scapulae, sternocleidomastoid, and semispinalis capitis. Mean (SD) TWSTRS total score was 41.2 (18.3) at baseline and 28.1 (16.3) at 4 week follow-up demonstrating a -12.5 (9.9) mean change or 32.1% improvement compared to baseline. Mean (SD) Pain NRS score (0-10) was 4.8 (3.1) at baseline and 3.5 (2.8) at 4-week follow-up demonstrating a -1.24 (2.6) mean change from baseline. 63.5% of physicians and 42.4% of patients rated much improved and very much improved for the CGIC and PGIC, respectively. Modified TSQM scores indicate that 83% of patients were generally satisfied with Dysport treatment. To date, 3 (1.4%) of patients reported adverse drug reactions and withdrew from the study.

Conclusions CONCLUSIONS: Cervical dystonia patients treated with abobotulinumtoxinA (Dysport) during cycle 1 reported improvements in the severity, disability and pain symptoms. 83% of subjects reported satisfaction with treatment.

Authors/Disclosures
Richard M. Trosch, MD, FAAN (Parkinson's and Movement Disorders Center) PRESENTER	Dr. Trosch has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Amneal . Dr. Trosch has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Neurocrine . Dr. Trosch has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boston Scientific.
Patricia B. Jozefczyk, MD	No disclosure on file
Daniel D. Truong, MD, FAAN (PMDI)	The institution of Dr. Truong has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Supernus. The institution of Dr. Truong has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amneal. The institution of Dr. Truong has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurocrine Biosciences. The institution of Dr. Truong has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Truong has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Truong has received research support from Abbvie. The institution of Dr. Truong has received research support from Aeon. The institution of Dr. Truong has received research support from Biogen. The institution of Dr. Truong has received research support from Bukwang. The institution of Dr. Truong has received research support from Cerevel. The institution of Dr. Truong has received research support from Eli Lilly. The institution of Dr. Truong has received research support from Enterin. The institution of Dr. Truong has received research support from Ipsen. The institution of Dr. Truong has received research support from Lundbeck. The institution of Dr. Truong has received research support from Neurocrine. The institution of Dr. Truong has received research support from Neuroderm. The institution of Dr. Truong has received research support from Parkinson Foundation. The institution of Dr. Truong has received research support from Prilenia. The institution of Dr. Truong has received research support from Revance. The institution of Dr. Truong has received research support from Sunovion. Dr. Truong has received publishing royalties from a publication relating to health care. Dr. Truong has received publishing royalties from a publication relating to health care. Dr. Truong has a non-compensated relationship as a President with International Association for Parkinsonism and Related Disorders that is relevant to AAN interests or activities.
Thomas A. Berger, MD (Dept. of Neurology, Medical University of Vienna)	Prof. Berger has received personal compensation in the range of $10,000-$49,999 for serving as a speaker at scientific meetings and participant of local and international advisory boards with various companies producing and markerting treatments for multiple sclerosis (Almirall, Biogen, Biologix, Bionorica, Celgene-BMS, Merck, Novartis, Roche, Sanofi-Genzyme, TG Therapeutics, UCB).
Mark F. Lew, MD, FAAN (USC School of Medicine)	Dr. Lew has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Supernus. Dr. Lew has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for kyowa. Dr. Lew has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for neurocrine. Dr. Lew has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acorda. Dr. Lew has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia. Dr. Lew has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RegenXBio. Dr. Lew has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurocrine. Dr. Lew has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Kyowa. Dr. Lew has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for acorda. The institution of Dr. Lew has received research support from MJFF. Dr. Lew has received research support from NIH.
Charles H. Adler, MD, PhD, FAAN (Mayo Clinic Arizona)	Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion. Dr. Adler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CND Life Sci. Dr. Adler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precon. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. The institution of Dr. Adler has received research support from NIH. The institution of Dr. Adler has received research support from Michael J. Fox Foundation. The institution of Dr. Adler has received research support from Arizona Biomedical Research Commission. Dr. Adler has received publishing royalties from a publication relating to health care.
Peter A. LeWitt, MD (Henry Ford Hospital - Franklin Pointe)	Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. LeWitt has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ONO Pharmaceuticals. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. The institution of Dr. LeWitt has received research support from Michael J Fox Foundation.
Carlos Singer, MD (University of Miami)	Dr. Singer has nothing to disclose.
Yavuz S. Silay, MD, CCRP (Ipsen Biopharmaceuticals Inc.)	No disclosure on file
	No disclosure on file
	No disclosure on file
Dominic Marchese, PharmD, RPh	No disclosure on file
Cynthia L. Comella, MD, FAAN (Rush University Medical Center)	Dr. Comella has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Comella has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vima. Dr. Comella has received publishing royalties from a publication relating to health care. Dr. Comella has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��